(Q45128205)

9 December 2017

title

Single-agent thalidomide for treatment of first relapse following high-dose chemotherapy in patients with multiple myeloma (English)

1 reference

9 December 2017

0 references

Fenk R

1

1 reference

9 December 2017

Hoyer B

2

1 reference

9 December 2017

Steidl U

3

1 reference

9 December 2017

Kondakci M

4

1 reference

9 December 2017

Graef T

5

1 reference

9 December 2017

Heuk R

6

1 reference

9 December 2017

Ruf L

7

1 reference

9 December 2017

Strupp C

8

1 reference

9 December 2017

Neumann F

9

1 reference

9 December 2017

Rohr UP

10

1 reference

9 December 2017

Hildebrandt B

11

1 reference

9 December 2017

Haas R

12

1 reference

9 December 2017

Kobbe G

13

1 reference

9 December 2017

language of work or name

1 reference

1 January 2005

1 reference

9 December 2017

1 reference

9 December 2017

volume

19

1 reference

9 December 2017

issue

1

1 reference

9 December 2017

page(s)

156-159

1 reference

Treatment of plasma cell dyscrasias with thalidomide and its derivatives

9 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403564

Thalidomide in multiple myeloma: current status and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403564

Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403564

Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403564

Thalidomide in patients with advanced multiple myeloma: a study of 83 patients--report of the Intergroupe Francophone du Myélome (IFM).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403564

Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403564

Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403564

An UK myeloma forum phase II study of thalidomide; long term follow-up and recommendations for treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403564

Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403564

21 January 2018

Identifiers

DOI

10.1038/SJ.LEU.2403564

1 reference

Dimensions Publication ID

9 December 2017

1030391307

0 references

1 reference